Is the Hole Only a Part of the Whole?⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.  by Block, Peter C.
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s the Hole Only
Part of the Whole?*
eter C. Block, MD
tlanta, Georgia
he presence of a patent foramen ovale (PFO) in patients
ith cryptogenic stroke has generated a rich debate over
hether the PFO is a culprit or a bystander. Arguably, the
attle lines are between cardiologists and neurologists. The
ormer have championed transcatheter PFO closure with a
itany of ingenious devices; the latter have insisted that
losure is unnecessary and that anticoagulation (usually with
arfarin) is proper therapy. The published studies in the last
5 years have been peppered with reports supporting either
ide and have generated some vexing questions along the
ay. For example, in the report by Mas et al. (1), why is the
ssociation of an atrial septal aneurysm (ASA) with a PFO
ssociated with stroke, but a PFO alone is not? Does the to
See page 655
nd fro motion of the ASA set up currents of blood flow
avoring right-to-left shunting or does thrombus form on
he ASA? Why does age seem to be a factor? Are there truly
ore bits of thromboembolic debris floating through the
ight side of the circulation as we age, thereby increasing the
isk of a particle being shunted right to left during a Valsalva
aneuver? In the PICSS (Patent Foramen Ovale In Cryp-
ogenic Stroke Study) trial (2), a substudy of the WARSS
Warfarin–Aspirin Recurrent Stroke Study) trial, the pres-
nce or absence of a PFO is equally associated with stroke.
On the other hand, closure of the PFO is supported by
eports from numerous cardiac centers interested in trans-
atheter therapies. None are randomized trials, but the
egistries seem to show that the incidence of recurrent
erebral events is decreased. The 1 question that those
egistries do not answer is: Why, if the PFO was indeed the
ulprit, do any recurrent events occur? Is incomplete closure
nd residual shunting the cause of recurrence, are there
verlooked sources of thromboembolism on the left side, are
he devices themselves a source of left-sided thrombus, or is
omething else going on?
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-t
ions or the American College of Cardiology.
From the Cardiology Department, Emory University Hospital, Atlanta, Georgia.Protagonists for both sides have long supported the
oncept of a randomized trial of closure versus anticoagulant
herapy. Multiple trials were begun, and failed for lack of
dequate enrollment, but now 1 trial, the CLOSURE
Evaluation of the STARFlex Septal Closure System in
atients With a Stroke or TIA Due to the Possible Passage
f a Clot of Unknown Origin Through a Patent Foramen
vale [PFO]) trial (3), using the STARFlex device (NMT
edical, Boston, Massachusetts) has been fully enrolled
nd the outcomes will be available in about 1.5 years. All of
s look forward to seeing those data.
But hold on. In this issue of JACC: Cardiovascular
nterventions, Rigatelli et al. (5) show data that shed a
ompletely different light on the possible mechanism of
ryptogenic stroke in the presence of a PFO, especially if a
arge ASA is also present. They postulated that in patients
ith PFO and ASA, there is left atrial (LA) dysfunction
imulating atrial fibrillation–like physiology, Studying al-
ost 100 patients with previous stroke referred for trans-
atheter PFO closure, they found that before closure, the
ubjects had significantly greater reservoir function, reduced
onduit function, and LA ejection fraction. Furthermore,
wo-thirds of the PFO patients also had moderate-to-large
SA, and of the patients with both PFO and ASA,
pontaneous echo contrast was seen in about one-half. None
f the patients with PFO alone had spontaneous echo
ontrast. These findings were similar to a group of patients
hat had atrial fibrillation! Not only that, but patients with
FO and ASA had worse functional parameters, a higher
ercentage of left-to-right shunting, and more coagulation
bnormalities than those with PFO alone, which might
ccount for the increased number of cerebral events seen in
hose patients pre-closure.
These are intriguing data, but any report has potential
aws, and this report is no exception. The authors do not
ell us what definition of ASA was used. It is not totally
lear if all parameters were measured as recommended (4),
nd the article does not report LA volume index. Whether
hese are important considerations will await larger patient
umbers and substantiation of the concept by other inves-
igators. Further, the report indicates a surprisingly high
ercentage of patients with abnormalities of the coagulation
ascade and patients that exhibited a “smoke-like phenom-
non” by at least 1 imaging tool. The picture of “smoke” in
he curl of the ASA seen by intracardiac echo and published
n the article is undeniable. However, most interventional
ardiologists and their echocardiographic colleagues have
een only rare patients exhibiting that phenomenon in their
eries of patients being evaluated for PFO closure. Do these
ata reflect some kind of selection bias?
To the authors’ credit, they restudied their patients after
losure. Active and passive emptying of the left atrium as
ell as conduit function and LA ejection fraction moved
oward normal levels of healthy control subjects. Three
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Block
Editorial Comment
664losure devices were used in their patients according to
natomic features of the atrial septum, but it is difficult to
each any conclusions about efficacy of one over the other
ue to the different anatomic baselines.
The report (5) makes provocative reading because it
oints out that the PFO may not have as large a role as we
hink in the cryptogenic stroke scenario. But for patients
ith PFO associated with ASA, the data of Rigatelli et al.
5) point out the increased potential of right-to-left shunt-
ng. The report indicates that the Mas et al. (1) report and
he PICSS report, which seem possibly contradictory, may
oth be correct. More importantly, their data show that LA
unction is clearly altered in the presence of a PFO and ASA
nd is similar to that of patients with atrial fibrillation,
hich might predispose them to a cardiac source of throm-
oembolism. It should be comforting to cardiologists that
he authors of this article contend that transcatheter PFO
losure returns LA function toward normal, which presum-
bly diminishes the risk of LA thrombus. But the devices
sed by the authors are large closure devices and influence
he ASA as well as close the PFO. Maybe size (or also
exibility) of the closure device is also important in restoring
A function. Not all closure devices may have the same
ffect on restoring LA function, especially small, suturelike
evices, and would therefore allow continued LA predispo-
ition to clot. That might help explain some of the recurrent
vent rate after transcatheter closure reported in the regis-
ries. The LA function might not have been restored toward
ormal in all patients. Take that thought a step further.
uppose the CLOSURE trial shows no benefit of PFO Klosure. That outcome might then be explained by the
evice’s possible lack of effect on the ASA and on restora-
ion of LA function (closure is necessary, but not enough).
ow that raises some interesting questions.
eprint requests and correspondence: Dr. Peter C. Block,
mory University Hospital, Cardiology, 1364 Clifton Road NE,
uite 606, Atlanta, Georgia 30322. E-mail: pblock@emory.edu.
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